Navigation Links
Valeant Pharmaceuticals Announces Public Offering Of Common Shares
Date:6/17/2013

ements can generally be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "should," "would," "intend," "seem," "potential," "appear," "continue," "future," believe," "estimate," "forecast," "project," variations of such words or other words that convey uncertainty of future events or outcome, although not all forward-looking statements contain these identifying words. Our forward-looking statements are subject to known and unknown risks and uncertainties, many of which are outside of our control and could cause actual results to differ materially and adversely from those expressed or implied by such statements. Those risks include, but are not limited to: our future economic performance, operating results, financial condition, capital resources or prospects; projections of revenue, expenses, income and losses, earnings (losses) per share, capital expenditures, dividends, growth rates or other financial items; market or industry trends, legal or regulatory developments; future events; the anticipated effect of acquisitions, litigation, new (or changes to existing) laws, regulations or accounting principles or other matters on our business, economic performance, operating results, financial condition, capital resources or prospects; our plans, objectives and strategies for future operations or otherwise; and our expectations and beliefs. Information concerning potential factors that could affect the Company's financial results is included in the Company's most recent annual or quarterly report and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after
'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... how to optimize a product,s web presence to ... critical. Brand websites, in particular, must meet the ... in regulations and culture. According ... LLC, more than half of the participating companies ...
(Date:12/19/2014)... 18, 2014 Somewhere between dropping five pounds ... forgotten. But Audicus , a next-generation hearing aids ... new year. Hearing loss is the third ... though it is often unaddressed. Forty-eight million Americans have ... hearing aid, mainly due to price. Hearing aids traditionally ...
(Date:12/19/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... results on Thursday, January 22, 2015, after the New York ... will be issued after 1:00 p.m. US Pacific Time and ... and future outlook. The earnings call is scheduled ... live webcast of the call can be accessed on ResMed,s ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Audicus Will Help People Resolve to Hear Better in 2015 2ResMed To Announce Second Quarter 2015 Results 2
... Continued Safety, Consistently Positive Clinical ... Results ... today from,Abbott,s SPIRIT III U.S. pivotal clinical trial demonstrated continued,positive, ... Stent System at one year, including continued,clinical superiority in major ...
... WASHINGTON, Oct. 22 The preliminary results ... OrbusNeich,s pro-healing stent, the,Genous Bio-engineered R stent, ... risk of restenosis patients show comparable efficacy ... de Winter, M.D., Ph.D.,principal investigator and director ...
Cached Medicine Technology:Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 2Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 5Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) and Boston Scientific's Taxus(R) Stent in Patients at High Risk of Restenosis 2
(Date:12/21/2014)... 22, 2014 In this report, ... by power source, product, and application. The market, ... and pneumatic instruments. By product, the market covers ... segments. The handpieces market is further subdivided into ... coagulators, laparoscopic instruments, shavers, wire/pin drivers, and others. ...
(Date:12/21/2014)... Khanna Vision Institute is pleased to ... Aspen Helicopters holiday event for underprivileged kids. The highlight ... flown by an aspen helicopter pilot. In the cover ... sleigh was visible.(please see accompanying video). Helicopter pilots require ... helped many pilots with Pi in eye vision correction. ...
(Date:12/21/2014)... Dennis Thompson HealthDay Reporter ... tobacco smokers find e-cigarettes less addictive than traditional cigarettes, new ... often as they did regular cigarettes, thousands of ex-smokers said ... impulsive and irritable over their need to smoke, researchers reported. ... score was significantly less for e-cig use than for tobacco ...
(Date:12/21/2014)... Francisco, California (PRWEB) December 21, 2014 ... his search for Vintage 1967 Jm Morrison and the Doors ... concert posters. This would also be the only time ... The concert was on Nov. 25, 1967. According to ... Washington D.C. They did play the Alexandria Roller Rink ...
(Date:12/21/2014)... Aliso Viejo, California (PRWEB) December 21, 2014 ... Film Studios have announced a new intro plugin for ... users to animate pictures, videos, logos, and more with ... Studios. “We’ve given our users the tools needed to ... Studios' ProMotion allows Final Cut Pro X users to ...
Breaking Medicine News(10 mins):Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... The number of cases of a new form of deadly ... and Canada, The SARS virus was first detected in South ... per reports from the World Health Organization the follwing cases ... up-to-date details as of May 23:// , ,Total number of ...
... to review the epidemiologic data on SARS.,Existing public ... disease in many countries and ,should be worked ... is now concentrated.,Crucial measures are taken to control ... like,detection and treatment of suspected cases as soon//,as ...
... a gene that might be responsible for asthma. Scientists ... the disease, hence leading to better,treatments. There are about ... person's susceptibility,to asthma. With combined efforts internationally, doctors have ... PHF11, was found on chromosome 13, a chromosome that ...
... A recent research findings indicates that treatments for both ... disorders. A study was conducted on people with migraine ... their psychiatric comorbidity was assessed, researchers found that the ... was three times higher than in individuals with no ...
... found that radiotherapy helps in natural tumor control process. ... When experiments were conducted on mice researchers identified an ... This enzyme destroys tumor nourishing blood vessels to die. ... it was thought that damage to the DNA in ...
... indicates teenagers are getting fatter not because they are ... when analysed data on diet, weight, and physical activity ... 10%, calorie intake rose 1%, while physical activity dropped ... active, they doesn't completely agree teens have not been ...
Cached Medicine News:Health News:Scientists review SARS 2
... Designed for Western, Northern, or ... three gels with dimensions as large ... and internal cooling base for temperature ... attached power leads. Additional ...
... a component of Bio-Rad's modular mini electrophoresis ... high-quality blotting of mini gels. Its modular ... cm gels in just 1 hour. Cooling ... which absorbs heat generated during transfers. The ...
... Includes: 2 gel holder cassettes, ... cables, fiber pads, blot absorbent ... The Trans-Blot transfer cell, used ... supply, performs efficient, high-intensity electrophoretic ...
... Flexibility for a ... Transfers. Native Enzyme, ... Transfers. Faster, Higher-Efficiency ... High Field-Intensity Transfers ...
Medicine Products: